|
| 36166003 | Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer. | Clin Cancer Res | 2022 |
| 36166003 | Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer. | Clin Cancer Res | 2022 |
| 33117705 | Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients. | Front Oncol | 2020 |
| 33117705 | Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients. | Front Oncol | 2020 |
| 35121931 | Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44. | Nat Cancer | 2020 |
| 35121931 | Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44. | Nat Cancer | 2020 |
| 28712979 | Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). | Clin Lung Cancer | 2018 |
| 28712979 | Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). | Clin Lung Cancer | 2018 |
| 29981926 | A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic Treatment. | J Thorac Oncol | 2018 |
| 29874546 | A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. | J Thorac Oncol | 2018 |
| 30652613 | Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial Documentation. | JCO Clin Cancer Inform | 2018 |
| 29217585 | Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. | Science | 2018 |
| 29382669 | Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. | Cancer Immunol Res | 2018 |
| 29981926 | A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic Treatment. | J Thorac Oncol | 2018 |
| 29874546 | A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. | J Thorac Oncol | 2018 |
| 30652613 | Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial Documentation. | JCO Clin Cancer Inform | 2018 |
| 29382669 | Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. | Cancer Immunol Res | 2018 |
| 29217585 | Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. | Science | 2018 |
| 29125624 | Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges. | Cancer | 2017 |
| 29125624 | Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges. | Cancer | 2017 |